Adjunctive fluoxetine improves global function in chronic schizophrenia
Abstract
Eight chronic schizophrenic inpatients received adjunctive fluoxetine (20 mg/day) for a mean of 10.6 weeks in an open clinical trial. Clinical state improved in all patients. Violent incidents decreased, while participation in programs and socialization increased.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).